Delivery Order SPE2DB24D1205-SPE2DB25FCZCL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,258.62 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages). The contract is a firm fixed price delivery order with an ultimate completion date of July 31, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same municipality. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) valued at $25,897.33. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract has a ceiling value of $6,349.14 and carries no set-aside designation. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) under a firm fixed-price contract valued at $16,247.74. The order was competitively awarded without set-aside provisions and has an ultimate completion date of July 23, 2025. AmerisourceBergen will perform this delivery from its corporate office location in Conshohocken, Pennsylvania, where the company is headquartered as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $15,877.85 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) under a firm fixed-price contract. The award was made on July 31, 2025, with an ultimate completion date of August 1, 2025, and represents a non-set-aside, competitively awarded delivery order. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its...
- The Defense Logistics Agency awarded a $17,006.14 delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) under a firm fixed price contract. The award was issued on July 30, 2025, with a completion date of July 31, 2025, and represents a competitively awarded, non-set-aside contract. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $41,875.77 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a...
- The Defense Logistics Agency awarded a delivery order valued at $17,178.08 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60 count) on July 21, 2025, with a completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $36,587.93 delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contractor, headquartered in Conshohocken, Pennsylvania, will perform all work...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) under a firm fixed price contract valued at $13,939.62. The delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZCLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) valued at $21,325.65 under a firm fixed-price contract. This non-set-aside award was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. This delivery order falls under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.99 million and extends through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying a comprehensive portfolio of brand-name and generic medications, vaccines, and medical supplies to support military and veteran healthcare systems. The Eliquis delivery represents a routine pharmaceutical procurement supporting the military health system's anticoagulant medication needs. The broader SPE2DX vehicle demonstrates the company's established capability to fulfill federal pharmaceutical supply requirements through open competition, positioning it as a prime vendor for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.3k | 7/31/25 |